Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy;Remodeling der extrazellulären matrix bei dilatativer kardiomyopathie

Herz

Volumn 27, Issue 7, 2002, Pages 677-682

  Pauschinger, Matthias ^a   Chandrasekharan, Kumaran ^b   Li, Jun ^b   Schwimmbeck, Peter Lothar ^b   Noutsias, Michel ^b   Schultheiss, Heinz Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Universitatsklin Benjamin Franklin ^*

Author keywords

Cytokines; Extracellular matrix; Matrix metalloproteinases; Myocarditis

Indexed keywords

COLLAGEN; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL TISSUE; AUTOCRINE EFFECT; CHRONIC DISEASE; COLLAGEN SYNTHESIS; DISEASE COURSE; EXTRACELLULAR MATRIX; HEART DILATATION; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; MYOCARDITIS; NONHUMAN; PARACRINE SIGNALING; PROTEIN DEGRADATION; REVIEW;

ANIMALS; CARDIOMYOPATHY, DILATED; CELLS, CULTURED; CHRONIC DISEASE; COLLAGEN; CYTOKINES; EXTRACELLULAR MATRIX; HEART FAILURE, CONGESTIVE; HOMEOSTASIS; HUMANS; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MYOCARDITIS; MYOCARDIUM; MYOCYTES, CARDIAC; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 18744378250     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-002-2413-4     Document Type: Review

References (49)

1. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro: TIMP-3 promotes apoptosis. J Clin Invest 1998;101:1478-87.
2. Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 2002;105:1983-8.
3. Czaja MJ, Weiner FR, Eghbali M, Giambrone MA, Eghbali M, Zern MA. Differential effects of gamma-interferon on collagen and fibronectin gene expression. J Biol Chem 1987;262:13348-51.
4. Edwards DR, Beaudry PP, Laing TD, Kowal V, Leco KJ, Leco PA, Lim MS. The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth. Int J Obes Relat Metab Disord 1996;20:S9-15.
5. Eghbali M, Tomek R, Sukhatme VP, Woods C, Bhambi B. Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 1991;69:483-90.
6. Eghbali M. Cardiac fibroblasts: Function, regulation of gene expression, and phenotypic modulation. Basic Res Cardiol 1992;87: Suppl 2:183-9.
7. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He CS. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci USA 1989;86:8207-11.
8. Gomis-Ruth FX, Maskos K, Betz M, et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997;389:77-81.
9. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996;271:30375-80.
10. Gunja-Smith Z, Morales AR, Romanelli R, et al. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 1996;148:1639-48.
11. He CS, Wilhelm SM, Pentland AP, et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989;86:2632-6.
12. Kadokami T, Frye C, Lemster B, Wagner CL, Feldman AM, McTiernan CF. Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation. 2001;104:1094-7.
13. Kajita M, Kinoh H, Ito N, Takamura A, Itoh Y, Okada A, Sato H, Seiki M. Human membrane type-4 matrix metalloproteinase (MT4-MMP) is encoded by a novel major transcript: Isolation of complementary DNA clones for human and mouse mt4-mmp transcripts. FEBS Lett 1999;457:353-6.
14. Kuhl U, Noutsias M, Seeberg B, Schannwell M, Welp LB, Schultheiss HP. Chronic inflammation in the myocardium of patients with clinically suspected dilated cardiomyopathy. J Card Fail 1994;1:13-25.
15. Lee AA, Delhaas T, McCulloch AD, Villarreal FJ. Differential responses of adult cardiac fibroblasts to in vitro biaxial strain patterns. J Mol Cell Cardiol 1999;31:1833-43.
16. Li J, Schwimmbeck PL, Tschope C, Leschka S, Husmann L, Rutschow S, Reichenbach F, Noutsias M, Kobalz U, Poller W, Spillman F, Zeichhardt H, Schultheiss H-P, Pauschinger M. Collagen degradation in a murine myocarditis model: Relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res (accepted).
17. Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998;98:1728-34.
18. Li YY, Kadokami T, Wang P, McTiernan CF, Feldman AM. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol 2002;282:H983-9.
19. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000;46:214-24.
20. Li YY, McTiernan CF, Feldman AM. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 1999;42:162-72.
21. Lijnen PJ, Petrov VV, Fagard RH. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J Renin Angiotensin Aldosterone Syst 2001;2:117-22.
22. Liu YE, Wang M, Greene J, et al. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol Chem 1997;272:20479-83.
23. Llano E, Pendas AM, Freije JP, Nakano A, Knauper V, Murphy G, Lopez-Otin C. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase A over-expressed in brain tumors. Cancer Res 1999;59:2570-6.
24. Miyamori H, Takino T, Seiki M, Sato H. Human membrane type-2 matrix metalloproteinase is defective in cell-associated activation of progelatinase A. Biochem Biophys Res Commun 2000;267:796-800.
25. Murphy G, Allan JA, Willenbrock F, et al. The role of the C-terminal domain in collagenase and stromelysin specificity. J Biol Chem 1992;267:9612-8.
26. Murphy G, Knauper V. Relating matrix metalloproteinase structure to function: Why the "hemopexin" domain? Matrix Biol 1997;15:511-8.
27. Neumann S, Huse K, Semrau R, Diegeler A, Gebhardt R, Buniatian GH, Scholz GH. Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 2002;39:756-60.
28. Noutsias M, Pauschinger M, Schultheiss H, Kuhl U. Phenotypic characterization of infiltrates in dilated cardiomyopathy - Diagnostic significance of T-lymphocytes and macrophages in inflammatory cardiomyopathy. Med Sci Monit 2002;8:CR478-87.
29. Okada Y, Gonoji Y, Naka K, et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 1992;267:21712-9.
30. Pauschinger M, Doerner A, Remppis A, Tannhäuser R, Kuehl U, Schultheiss H-P. Differential myocardial gene expression of collagen type I and type III in dilated cardiomyopathy: Effects of myocardial inflammation. Cardiovasc Res 1998;37:123-9.
31. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, Kuehl U, Schultheiss HP. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 1999;99:2750-6.
32. Prockop DJ, Kivirikko KI. Collagens: Molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995;64:403-34.
33. Saed GM, Zhang W, Diamond MP. Effect of hypoxia on stimulatory effect of TGF-beta 1 on MMP-2 and MMP-9 activities in mouse fibroblasts. J Soc Gynecol Invest 2000;7:348-54.
34. Shimada T, Nakamura H, Ohuchi E, Fujii Y, Murakami Y, Sato H, Seiki M, Okada Y. Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase. Eur J Biochem 1999;262:907-14.
35. Simm A, Nestler M, Hoppe V. Mitogenic effect of PDGF-AA on cardiac fibroblasts. Basic Res Cardiol 1998;93:Suppl 3:40-3.
36. Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted over-expression of tumor necrosis factor. Circulation 2001;104:826-31.
37. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000;86:1259-65.
38. Spinale FG. Matrix metalloproteinases: Regulation and Dysregulation in the Failing Heart. Circ Res 2002;90:520.
39. Spinale FG, Coker ML, Heung LI, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000;102:1944-9.
40. Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT, Zile MR. Matrix metalloproteinase inhibition during the development of congestive heart failure: Effects on left ventricular dimensions and function. Circ Res 1999;85:364-76.
41. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998;97:1708-15.
42. Velasco G, Cal S, Merlos-Suarez A, Ferrando AA, Alvarez S, Nakano A, Arribas J, Lopez-Otin C. Human MT 6-matrix metalloproteinase: Identification, progelatinase A activation, and expression in brain tumors. Cancer Res 2000;60:877-82.
43. Weber KT, Sun Y, Katwa LC, Cleutjens JP. Connective tissue: A metabolic entity? J Mol Cell Cardiol 1995;27:107-20.
44. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: Function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994;26:279-92.
45. Wilson EM, Spinale FG. Myocardial remodelling and matrix metalloproteinases in heart failure: Turmoil within the interstitium. Ann Med 2001;33:623-34.
46. Woessner JF Jr, Nagase H. Activation of the zymogen forms of MMPs. In: Matrix Metalloproteinases and TIMPs. New York: Oxford University Press, 2000:72-86.
47. Woessner JF Jr, Nagase H. Functions of the TIMPs. In: Matrix Metalloproteinases and TIMPs. New York: Oxford University Press, 2000:130-5.
48. Woessner JF Jr, Nagase H. Introduction to the matrix metalloproteinases (MMPs).In: Matrix Metalloproteinases and TIMPs. New York: Oxford University Press, 2000:1-10.
49. Woessner JF Jr. The matrix metalloproteinase family. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego: Academic Press, 1998:1-14.